WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H329401
CAS#: 30578-37-1
Description: Amezinium Metilsulfate, also known as Regulton and LU-1631, is a norepinephrine reuptake inhibitor which exclusively affects postganglionic sympathetic neurons. Amezinium Metilsulfate is used to treat hypotension.
Hodoodo Cat#: H329401
Name: Amezinium Metilsulfate
CAS#: 30578-37-1
Chemical Formula: C12H15N3O5S
Exact Mass: 0.00
Molecular Weight: 313.328
Elemental Analysis: C, 46.00; H, 4.83; N, 13.41; O, 25.53; S, 10.23
Synonym: Amezinium Metilsulfate; LU-1631; LU 1631; LU1631; Regulton; Risumic
IUPAC/Chemical Name: 4-amino-6-methoxy-1-phenylpyridazin-1-ium methyl sulfate
InChi Key: ZEASXVYVFFXULL-UHFFFAOYSA-N
InChi Code: InChI=1S/C11H11N3O.CH4O4S/c1-15-11-7-9(12)8-13-14(11)10-5-3-2-4-6-10;1-5-6(2,3)4/h2-8,12H,1H3;1H3,(H,2,3,4)
SMILES Code: COC1=CC(N)=CN=[N+]1C2=CC=CC=C2.O=S(OC)([O-])=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 313.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Kobayashi M. Diffuse cerebrovascular dilation: Case report of amezinium metilsulfate-induced reversible cerebral vasoconstriction syndrome. Cephalalgia. 2016 Mar;36(3):289-93. doi: 10.1177/0333102415588326. PubMed PMID: 26016487.
2: Sakakibara R, Uchiyama T, Asahina M, Yoshiyama M, Yamanishi T, Hattori T. Amezinium metilsulfate, a sympathomimetic agent, may increase the risk of urinary retention in multiple system atrophy. Clin Auton Res. 2003 Feb;13(1):51-3. PubMed PMID: 12664248.
3: Harada K, Ohmori M, Fujimura A, Ohashi K. Effect of amezinium metilsulfate on the finger skin vasoconstrictor response to cold stimulation and venoconstrictor response to noradrenaline. Jpn Circ J. 1998 Nov;62(11):824-8. PubMed PMID: 9856598.
4: Adachi N, Kondo A, Hayashi K. [A case of successful treatment of postprandial syncope with combined use of amezinium metilsulfate and dihydroergotamine mesylate]. Nihon Ronen Igakkai Zasshi. 1999 Jul;36(7):499-502. Japanese. PubMed PMID: 10536458.
5: Noma K, Miyazaki H, Anzawa R, Miyoshi K, Hayashi Y, Arino T, Nishide R, Seki S, Mochizuki S. [Effects of oral amezinium metilsulfate in patients with sick sinus syndrome]. J Cardiol. 1997 Jul;30(1):29-35. Japanese. PubMed PMID: 9253693.
6: Nambu K, Yoshida K, Kagemoto A, Matsumoto K, Miyazaki H, Hashimoto M, Esumi Y, Jin Y, Gunji S, Iwabuchi M, et al. Disposition and metabolism of [14C]-amezinium metilsulfate in rats. Arzneimittelforschung. 1988 Jul;38(7):909-18. PubMed PMID: 3207436.
7: Kita K, Hirayama K. Treatment of neurogenic orthostatic hypotension with amezinium metilsulfate, a new indirect sympathomimetic drug. Neurology. 1988 Jul;38(7):1095-9. PubMed PMID: 3386828.
8: Sannomiya K, Kudo Y, Mori T, Nakazato O, Okajima T. [A case of acute idiopathic pandysautonomia]. Rinsho Shinkeigaku. 1989 Jul;29(7):895-900. Japanese. PubMed PMID: 2805514.
